FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 277 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Reflections May 26, 2021 To Treat Pancreatic Cancer, Mouse Study Suggests Altering Tumor Microbiome September 9, 2019 FDA Says Breast Implant Cancer Risk Is Not Enough to Warrant... May 3, 2019 PD1 and LAG3 Inhibition Plus Chemoradiotherapy in the Neoadjuvant Setting for... March 28, 2024 Load more HOT NEWS FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic NSCLC with EGFR... Trial Tests Abemaciclib As New Option for Early-Stage Breast Cancer EMA Recommends Granting a Marketing Authorisation for Plerixafor Accord More Evidence that One HPV Vaccine Dose Protects against Cancer-Causing Infections
